Connexion
Connexion
Ou se connecter avec
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Inscription
Ou se connecter avec
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ASTELLAS PHARMA INC.

(4503)
  Rapport
Temps Différé Japan Exchange  -  08:00 22/09/2022
1904.50 JPY   -1.86%
12/09Seagen, Merck, Astellas publient les données d'un essai de Padcev et Keytruda pour le traitement du cancer de la vessie
MT
12/09Astellas, Seagen et Merck annoncent les résultats d'une étude clinique portant sur PADCEV(R) (Enfortumab Vedotin-Ejfv) avec KEYTRUDA((R) (Pembrolizumab) et PADCEV en monothérapie dans le cancer urothélial avancé de première intention
CI
05/09Astellas Pharma Inc. Annonce les premiers résultats de l'étude de phase 3 sur l'innocuité à long terme du fezolinetant en Chine continentale
CI
SynthèseCotationsGraphiquesActualitésNotationsAgendaSociétéFinancesConsensusRévisionsDérivésFonds 
SynthèseToute l'actualitéAutres languesCommuniquésPublications officiellesActualités du secteur
Actualités dans d'autres langues sur ASTELLAS PHARMA INC.
20/09Astellas and MBC BioLabs Announce Astellas Future Innovator Prize to Help Biotech Start..
12/09Seagen, Merck, Astellas Release Data From Trial of Padcev, Keytruda to Treat Bladder Ca..
12/09Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating PADCEV(R) (..
05/09Astellas Pharma Inc. Announces Topline Results from Phase 3 Long-Term Safety Study of F..
19/08Astellas Pharma Gets US FDA Nod on New Drug Application for Menopause
18/08ADRs End Lower, Geely Automobile Trades Actively
18/08U.S. FDA Accepts Astellas' New Drug Application for Fezolinetant
10/08Verizon Business selected to transform Astellas Pharma's global network infrastructure
10/08Verizon Communications Unit Wins Network Management Contract From Astellas Pharma
09/08Astellas Oncology Announces Grand Prize Winner in Annual C3 Prize to Cultivate Innovati..
02/08Astellas Pharma Shares Sink 3% as Weak Yen Drags Fiscal Q1 Attributable Profit Down
02/08Astellas Pharma Inc. Announces Executive Changes
01/08TRANSCRIPT : Astellas Pharma Inc., Q1 2023 Earnings Call, Aug 01, 2022
01/08ASTELLAS PHARMA : Financial Results (Q1/FY2022)
01/08ASTELLAS PHARMA : Presentation Material for Information Meeting (Q1/FY2022)
01/08ASTELLAS PHARMA : Supplementary Documents (Q1/FY2022)
27/07Astellas and Seagen Announce Positive Topline Results For PADCEV (enfortumab vedotin-ej..
27/07Nikkei 225 Up 0.2% Ahead of Federal Reserve Announcement
27/07Japan's Nikkei ends higher helped by chip stocks gains
27/07Japan's Nikkei little changed ahead of Fed meeting outcome
26/07SECTOR UPDATE : Health Care Stocks Steady Premarket Tuesday
26/07Seagen, Astellas Report Positive Results for Trials on Padcev with Keytruda as Treatmen..
26/07Astellas-Seagen's Bladder Cancer Therapy Shrinks Tumor in Phase 1b/2 Trial
26/07ASTELLAS PHARMA : and Seagen Announce Positive Topline Results For PADCEV with KEYTRUDA as..
26/07Astellas and Seagen Announce Positive Topline Results For PADCEV® (enfortumab vedotin-e..
22/07Astellas Pharma Inc. Unveils Plans to Open New Biotech Campus in South San Francisco
21/07Dolphin Unit Closes $8 Million Purchase of High Reserve F&B in Cash-Stock Deal; Dolphin..
05/07Mogrify and Astellas Announces Collaboration to Conduct Research on in Vivo Regenerativ..
28/06Sutro Biopharma Shares Rise 24% After Collaboration With Astellas Pharma
28/06Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Nove..
28/06Sutro Biopharma Shares Soar 67% on Cancer Treatment Collaboration with Astellas
27/06Astellas Announces FDA Update on the FORTIS Clinical Trial of AT845 in Adults with Late..
27/06Astellas Pharma Inc. Announces FDA Update on Fortis Clinical Trial of AT845 in Adults w..
24/06WE PUBLISHED A STORY : “Astellas' Path to Sustainability Vol.1: A New Materiality Ma..
24/06ASTELLAS' PATH TO SUSTAINABILITY VOL : A New Materiality Matrix as a Compass to Direct our..
24/06Astellas Submits Fezolinetant New Drug Application to U.S. FDA
08/06Astellas Pharma Inc. Celebrates Opening of Large-Scale Gene Therapy Manufacturing Facil..
02/06Nikkei 225 Down 0.2% on Wall Street Cues, Central Bank Outlooks
02/06Japan's Nikkei edges back from 6-week high as Astellas, Sony drag
02/06Japan's Nikkei retreats from 6-week high as Astellas, Sony drag
26/05ASTELLAS PHARMA : Posted Notice of Convocation of the 17th Term Annual Shareholders Meetin..
26/05ASTELLAS PHARMA : Notice of Convocation of the 17th Term Annual Shareholders Meetingᦀ..
24/05Amphastar Pharmaceuticals Secures FDA Approval for Regadenoson
23/05Astellas Pharma to Appeal US Court Decision on Patent Infringement Lawsuit
20/05ASTELLAS PHARMA : Confirms Unfavorable District Court Decision in LEXISCAN® 0.4mg/mL U.S. ..
12/05Astellas Pharma Inc. Highlights Data on Advanced and Rare Cancers during 2022 ASCO Annu..
09/05Twist Bioscience Signs Research Collaboration, Exclusive Option License Deal With Astel..
09/05Twist Bioscience Enters into Research, Exclusive Option and License Agreement with Aste..
05/05Astellas Pharma Inc. to Present 12-Week Data from Pivotal Phase 3 SKYLIGHT 1™ Tria..
27/04MÄRKTE ASIEN/Tokio und Seoul schwach - Erholungsrally in Schanghai
27/04TRANSCRIPT : Astellas Pharma Inc., 2022 Earnings Call, Apr 27, 2022
27/04ASTELLAS PHARMA : Changes of Representative Director and Directors
27/04ASTELLAS PHARMA : Financial Results (FY2021)
27/04ASTELLAS PHARMA : Supplementary Documents (FY2021)
27/04ASTELLAS PHARMA : Presentation Material for Information Meeting (FY2021)
26/04Astellas Oncology Now Accepting Applications for Annual C3 Prize to Cultivate Innovatio..
25/04MÄRKTE ASIEN/Sehr schwach - Kursdebakel in Schanghai
25/04The University of Tokyo and Astellas Pharma Inc. Enter Second Phase of Strategic Partne..
25/04Astellas Pharma to Record $389 Million Impairment Loss on Products under Development
22/04ASTELLAS PHARMA : Notice Regarding Impairment Loss for Products under Development
22/04Astellas Pharma Inc. Provides Impairment Guidance for the Fourth Quarter Ended March 31..
14/04ASTELLAS PHARMA : European Commission Approves PADCEV (enfortumab vedotin) for Locally Adv..
13/04Seagen-Astellas Pharma Treatment for Urothelial Cancer Gets European Commission Nod
13/04Astellas Pharma Inc. and Seagen Inc. Announces European Commission Approves PADCEV™..
13/04European Commission Approves Drug for Urothelial Cancer
11/04Nikkei 225 Off 0.6% on Russia Outlook, Inflation Concerns
07/04Nikkei 225 Slides 1.97%, Extends Losses on Federal Reserve Outlook; IMF Cuts Japan GDP ..
07/04Japan's Nikkei sinks most in a month on Fed, China worries
07/04Japan's Nikkei hits 3-week low on Fed, China worries
05/04Singlera Genomics Announces Research Collaboration with Astellas Pharma Pursuing Methyl..
05/04WE PUBLISHED A NEW SUSTAINABILITY SE : “Developing a sustainable society by leveragi..
04/04Japan's Nikkei falls as chip shares track U.S. peers lower
01/04Australian Shares Post Small Loss Amid Decline in Business Confidence
01/04ASTELLAS PHARMA : We published a Drug Research page.
31/03Global Health Innovative Technology Fund Announces Collaboration with Astellas Pharma I..
15/03ASTELLAS PHARMA : Initiatives for Gene Therapy(2,933KB)
15/03Astellas Pharma Inc. Announces Topline 12-Week Results from Phase 3 Study of Fezolineta..
14/03WE PUBLISHED A STORY : “Reinvigorating the immune system to find new ways to cure ca..
14/03ASTELLAS PHARMA : Reinvigorating the immune system to find new ways to cure cancer
11/03Astellas Pharma Completes $428 Million Share Buyback
10/03Genetic Leap and Astellas Establish Research Collaboration to Develop RNA-targeted Smal..
10/03ASTELLAS PHARMA : Meeting Script(8,030KB)
10/03ASTELLAS PHARMA : Announces Completion of Acquisition of Own Shares, and Cancellation of T..
10/03Tranche Update on Astellas Pharma Inc.'s Equity Buyback Plan announced on February 2, 2..
09/03ASTELLAS PHARMA : Update on ukraine
09/03TRANSCRIPT : Astellas Pharma Inc. - Special Call
09/03ASTELLAS PHARMA : Presentation Material for R&D Meeting
09/03ASTELLAS PHARMA : Initiatives for Gene Therapy(2,929KB)
09/03ASTELLAS PHARMA : Updated “R&D meeting” Section
09/03Astellas Pharma Inc.'s Equity Buyback announced on February 2, 2022, has expired with 2..
07/03Astellas Announces Topline Results from Long-Term Phase 3 Safety Study of Fezolinetant ..
07/03ASTELLAS PHARMA : Announces Topline Results from Long-Term Phase 3 Safety Study of Fezolin..
02/03Astellas Pharma Repurchases Shares for $255 Million
02/03WE PUBLISHED A STORY : “Astellas' VALUE powered by people—New Challenge of HR...
02/03ASTELLAS PHARMA : ' VALUE powered by people — New Challenge of HR
01/03ASTELLAS PHARMA : Meeting Script(4,467KB)
01/03ASTELLAS PHARMA : Announces Status of Acquisition of Own Shares
01/03Japanese shares rise on bargain-hunting, hopes for Russia-Ukraine talks
01/03ASTELLAS PHARMA : and Seagen Announce CHMP Confirms Positive Opinion for PADCEV (enfortuma..
01/03ASTELLAS PHARMA : Affinivax Reacquires Rights from Astellas for ASP3772, a Novel 24-valent..
Prochain événement sur ASTELLAS PHARMA INC.